Cite
APA Citation
Dörner, T., Posch, M. G., Li, Y., Petricoul, O., Cabanski, M., Milojevic, J. M., Kamphausen, E., Valentin, M., Simonett, C., Mooney, L., Hüser, A., Gram, H., Wagner, F. D., & Oliver, S. J. (2019). treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Annals of the rheumatic diseases, 78(5), 641–. http://access.bl.uk/ark:/81055/vdc_100130162925.0x000057